These studies provide the first evidence that IR induces high levels of PAF and ox-GPC PAF-R agonists that block anti-tumor immunity via systemic PAF-R signaling in a process that can be ameliorated via COX-2 inhibitors. The gene discussed is PTAFR; the disease is neoplasm.